Literature DB >> 10438350

Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.

R B Moss1, M R Wallace, W K Giermakowska, E Webb, J Savary, C Chamberlin-Brandt, G Theofan, R Musil, S P Richieri, F C Jensen, D J Carlo.   

Abstract

It was hypothesized that immune recognition could be stimulated with combined immune-based and potent antiviral drug therapies. This study examined human immunodeficiency virus type 1 (HIV-1)-specific lymphocyte proliferation before and after treatment with an inactivated HIV-1 immunogen in 15 chronically infected HIV-1 seropositive subjects. Lymphocyte proliferation to the immunizing antigen (gp120-depleted HIV-1; P<.001), purified native p24 (P<.001), and recombinant p24 (P<.05) increased after treatment with the HIV-specific immune-based therapy. By HIV-1 antigen-specific flow cytometry, T helper CD4 lymphocytes, CD8 lymphocytes, and NK cells (all P<.001) were the predominant cell types proliferating in vitro after treatment. Additional phenotyping of proliferating cells revealed predominantly CD4 and CD8 memory (both P<.001) phenotypes. This study supports the concept that in vitro lymphocyte proliferation to HIV-1 antigens, augmented after treatment with an inactivated HIV-1 immunogen, involves primarily CD4 and CD8 cell memory immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438350     DOI: 10.1086/314924

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

2.  Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.

Authors:  Wataru Akahata; Zhi-yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).

Authors:  R B Moss; W Giermakowska; M R Wallace; J Savary; F Jensen; D J Carlo
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

Review 4.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection.

Authors:  Nesrina Imami; Antonio Pires; Gareth Hardy; Jamie Wilson; Brian Gazzard; Frances Gotch
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.

Authors:  Jane Gamberg; Lisa Barrett; Ian Bowmer; Constance Howley; Michael Grant
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.542

7.  Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.

Authors:  Anna A Herasimtschuk; Samantha J Westrop; Graeme J Moyle; Jocelyn S Downey; Nesrina Imami
Journal:  J Immune Based Ther Vaccines       Date:  2008-10-31

8.  A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.

Authors:  Gareth Ad Hardy; Nesrina Imami; Mark R Nelson; Ann K Sullivan; Ron Moss; Marlén Mi Aasa-Chapman; Brian Gazzard; Frances M Gotch
Journal:  J Immune Based Ther Vaccines       Date:  2007-04-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.